Please use this identifier to cite or link to this item:
https://ahro.austin.org.au/austinjspui/handle/1/16735
Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Vuckovic, Slavica | - |
dc.contributor.author | Vandyke, Kate | - |
dc.contributor.author | Rickards, David A | - |
dc.contributor.author | McCauley Winter, Padraig | - |
dc.contributor.author | Brown, Simon HJ | - |
dc.contributor.author | Mitchell, Todd W | - |
dc.contributor.author | Liu, Jun | - |
dc.contributor.author | Lu, Jun | - |
dc.contributor.author | Askenase, Philip W | - |
dc.contributor.author | Yuriev, Elizabeth | - |
dc.contributor.author | Capuano, Ben | - |
dc.contributor.author | Ramsland, Paul A | - |
dc.contributor.author | Hill, Geoffrey R | - |
dc.contributor.author | Zannettino, Andrew CW | - |
dc.contributor.author | Hutchinson, Andrew T | - |
dc.date | 2017-02-17 | - |
dc.date.accessioned | 2017-07-27T03:18:00Z | - |
dc.date.available | 2017-07-27T03:18:00Z | - |
dc.date.issued | 2017-05 | - |
dc.identifier.citation | British Journal of Haematology 2017; 177(3): 423-440 | en_US |
dc.identifier.uri | https://ahro.austin.org.au/austinjspui/handle/1/16735 | - |
dc.description.abstract | We have discovered that a small cationic molecule, GW4869, is cytotoxic to a subset of myeloma cell lines and primary myeloma plasma cells. Biochemical analysis revealed that GW4869 binds to anionic phospholipids such as phosphatidylserine - a lipid normally confined to the intracellular side of the cell membrane. However, interestingly, phosphatidylserine was expressed on the surface of all myeloma cell lines tested (n = 12) and 9/15 primary myeloma samples. Notably, the level of phosphatidylserine expression correlated well with sensitivity to GW4869. Inhibition of cell surface phosphatidylserine exposure with brefeldin A resulted in resistance to GW4869. Finally, GW4869 was shown to delay the growth of phosphatidylserine-high myeloma cells in vivo. To the best of our knowledge, this is the first example of using a small molecule to target phosphatidylserine on malignant cells. This study may provide the rationale for the development of phosphatidylserine-targeting small molecules for the treatment of surface phosphatidylserine-expressing cancers. | en_US |
dc.subject | GW4869 | en_US |
dc.subject | Multiple myeloma | en_US |
dc.subject | Phosphatidylserine | en_US |
dc.subject | Small molecule | en_US |
dc.title | The cationic small molecule GW4869 is cytotoxic to high phosphatidylserine-expressing myeloma cells | en_US |
dc.type | Journal Article | en_US |
dc.identifier.journaltitle | British Journal of Haematology | en_US |
dc.identifier.affiliation | The Bone Marrow Transplantation Laboratory, QIMR Berghofer Medical Research Institute, Brisbane, Queensland, Australia | en_US |
dc.identifier.affiliation | School of Medicine, University of Queensland, Brisbane, Queensland, Australia | en_US |
dc.identifier.affiliation | Mater Research, Translational Research Institute, Brisbane, Queensland, Australia | en_US |
dc.identifier.affiliation | Faculty of Health and Medical Sciences, SA Pathology, The University of Adelaide, Adelaide, SA, Australia | en_US |
dc.identifier.affiliation | Cancer Theme, South Australian Health and Medical Research Institute, SA Pathology, Adelaide, SA, Australia | en_US |
dc.identifier.affiliation | School of Life Sciences, Centre for Health Technologies and the iThree Institute, University of Technology Sydney, Ultimo, NSW, Australia | en_US |
dc.identifier.affiliation | School of Biology and Illawarra Health and Medical Research Institute, University of Wollongong, Wollongong, NSW, Australia | en_US |
dc.identifier.affiliation | Department of Genetics, Yale Stem Cell Center, Yale Cancer Center and Yale Center for RNA Science and Medicine, New Haven, CT, USA | en_US |
dc.identifier.affiliation | Section of Allergy and Clinical Immunology, Department of Internal Medicine, Yale School of Medicine, New Haven, CT, USA | en_US |
dc.identifier.affiliation | Medicinal Chemistry, Monash Institute of Pharmaceutical Sciences, Monash University, Parkville, Victoria, Australia | en_US |
dc.identifier.affiliation | School of Science, RMIT University, Bundoora, Victoria, Australia | en_US |
dc.identifier.affiliation | Centre for Biomedical Research, Burnet Institute, Melbourne, Victoria, Australia | en_US |
dc.identifier.affiliation | Department of Immunology, Monash University, Alfred Medical Research and Education Precinct, Melbourne, Victoria, Australia | en_US |
dc.identifier.affiliation | Department of Surgery Austin Health, University of Melbourne, Victoria, Australia | en_US |
dc.identifier.affiliation | Department of Bone Marrow Transplantation, The Royal Brisbane and Women's Hospital, Herston, , Queensland, Australia | en_US |
dc.identifier.pubmeduri | https://pubmed.ncbi.nlm.nih.gov/28211573 | en_US |
dc.identifier.doi | 10.1111/bjh.14561 | en_US |
dc.type.content | Text | en_US |
dc.type.austin | Journal Article | en_US |
local.name.researcher | Ramsland, Paul A | |
item.openairetype | Journal Article | - |
item.cerifentitytype | Publications | - |
item.grantfulltext | none | - |
item.fulltext | No Fulltext | - |
item.openairecristype | http://purl.org/coar/resource_type/c_18cf | - |
crisitem.author.dept | Surgery (University of Melbourne) | - |
Appears in Collections: | Journal articles |
Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.